Thomas J. Scriba

20.4k citations

206 papers · 9.2k indexed · 3 hit papers · h-index 50

Impact in

Infectious Diseases top 0.1%
- Tuberculosis Research and Epidemiology
Immunology top 0.2%
- Immunodeficiency and Autoimmune Disorders
- Immune responses and vaccinations
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses

Papers in

Infectious Diseases 139
- Tuberculosis Research and Epidemiology 130
Immunology 116
- Immunodeficiency and Autoimmune Disorders 53
- Immune responses and vaccinations 39
- Immune Cell Function and Interaction 38
- T-cell and B-cell Immunology 30

Co-authors: Willem A. Hanekom Mark Hatherill Gregory Hussey Hassan Mahomed Gerhard Walzl Michèle Tameris Helen McShane Mark M. Davis
Journals: Frontiers in Immunology (16 papers)The Journal of Immunology (15 papers)PLoS ONE (14 papers)American Journal of Respiratory and Critical Care Medicine (9 papers)Vaccine (8 papers)
Partner nations: South Africa United States United Kingdom

In The Last Decade

Thomas J. Scriba

198 papers receiving 9.0k citations

Hit Papers

align trajectories log scale

Identifying specificity groups in the T cell receptor repertoire 2017 · 595 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Nature
2013 The Lancet
2011 Nature reviews. Immunology

Peers

Countries citing papers authored by Thomas J. Scriba

Since Specialization

Citations

This map shows the geographic impact of Thomas J. Scriba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Scriba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Scriba more than expected).

Fields of papers citing papers by Thomas J. Scriba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas J. Scriba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Scriba. The network helps show where Thomas J. Scriba may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas J. Scriba, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas J. Scriba Line = papers co-authored together Thomas J. Scriba links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines Cell ·Samuel J. Vidal, Ninaad Lasrado, Lisa H. Tostanoski, Jayeshbhai Chaudhari, Esther Mbiwan, Ganad Neka, Ellis Strutton, Ángel Pérez, Daniel Sellers, Julia Barrett, Michelle A. Lifton, Shoko Wakabayashi, Behnaz Eshaghi, Erica N. Borducchi, Malika Aïd, Wenjun Li, Thomas J. Scriba, Ana Jaklenec, Robert Langer, Dan H. Barouch	2025	1
2	OMIP‐101: 27‐color flow cytometry panel for immunophenotyping of major leukocyte populations in fixed whole blood Cytometry Part A ·Claire Imbratta, Timothy D. Reid, Asma Toefy, Thomas J. Scriba, Elisa Nemes	2024	3
3	Mtb-Specific HLA-E-Restricted T Cells Are Induced during Mtb Infection but Not after BCG Administration in Non-Human Primates and Humans Vaccines ·Linda Voogd, Marjolein van Wolfswinkel, Iman Satti, Andrew White, Karin Dijkman, Anele Gela, Krista E. van Meijgaarden, Kees L. M. C. Franken, Julia L. Marshall, Tom H. M. Ottenhoff, Thomas J. Scriba, Helen McShane, Sally Sharpe, Frank A. W. Verreck, Simone A. Joosten	2024	2
4	Estimating the Potential Public Health Value of BCG Revaccination The Journal of Infectious Diseases ·Rebecca A. Clark, Tom Sumner, Chathika K. Weerasuriya, Roel Bakker, Thomas J. Scriba, Richard G. White	2024	2
5	Single-cell profiling reveals distinct subsets of CD14+ monocytes drive blood immune signatures of active tuberculosis Frontiers in Immunology ·Hannah Hillman, Nabeela Khan, Akul Singhania, Paige Dubelko, Ferran Soldevila, Rashmi Tippalagama, Aruna Dharshan De Silva, Bandu Gunasena, Judy Perera, Thomas J. Scriba, Cynthia Ontong, Michelle Fisher, Angelique Kany Kany Luabeya, Randy Taplitz, Grégory Seumois, Pandurangan Vijayanand, Catherine C. Hedrick, Bjoern Peters, Julie G. Burel	2023	12
6	Newborn bacille Calmette-Guérin vaccination induces robust infant interferon-γ-expressing natural killer cell responses to mycobacteria International Journal of Infectious Diseases ·Melissa Murphy, Sara Suliman, Libby Briel, Helen Veldtsman, Nondumiso Khomba, Hadn Africa, Marcia Steyn, Candice Snyders, Ilana C. van Rensburg, Gerhard Walzl, Novel N. Chegou, Mark Hatherill, Willem A. Hanekom, Thomas J. Scriba, Elisa Nemes	2023	5
7	Poly(ADP-ribose) polymerase 9 mediates early protection against Mycobacterium tuberculosis infection by regulating type I IFN production Journal of Clinical Investigation ·Shyamala Thirunavukkarasu, Mushtaq Ahmed, Bruce A. Rosa, Mark Boothby, Sung Hoon Cho, Javier Rangel‐Moreno, Stanley Kimbung Mbandi, Valérie Schreiber, Ananya Gupta, Joaquı́n Zúñiga, Makedonka Mitreva, Deepak Kaushal, Thomas J. Scriba, Shabaana A. Khader	2023	12
8	Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR SHILAP Revista de lepidopterología ·Simon C. Mendelsohn, Stanley Kimbung Mbandi, Andrew Fioré-Gartland, Adam Penn‐Nicholson, Munyaradzi Musvosvi, Humphrey Mulenga, Michelle Fisher, Katie Hadley, Mzwandile Erasmus, Onke Nombida, Michèle Tameris, Gerhard Walzl, Kogieleum Naidoo, Gavin Churchyard, Mark Hatherill, Thomas J. Scriba	2022	20
9	Expression of specific HLA class II alleles is associated with an increased risk for active tuberculosis and a distinct gene expression profile HLA ·Leila Y. Chihab, Rebecca Kuan, Elizabeth J. Phillips, S. Mallal, Virginie Rozot, Mark M. Davis, Thomas J. Scriba, Alessandro Sette, Bjoern Peters, Cecilia S. Lindestam Arlehamn, (unknown)	2022	10
10	Utility of a three-gene transcriptomic signature in the diagnosis of tuberculosis in a low-endemic hospital setting Infectious Diseases ·Bih H. Chendi, Tracey Jooste, Thomas J. Scriba, Martin Kidd, Simon C. Mendelsohn, Kristian Tonby, Gerhard Walzl, Anne Ma Dyrhol‐Riise, Novel N. Chegou	2022	2
11	T Cells Specific for a Mycobacterial Glycolipid Expand after Intravenous Bacillus Calmette–Guérin Vaccination The Journal of Immunology ·Erik D. Layton, Soumik Barman, Damien B. Wilburn, Krystle K. Q. Yu, Malisa T. Smith, John D. Altman, Thomas J. Scriba, Nabil Tahiri, Adriaan J. Minnaard, Mario Roederer, Robert A. Seder, Patricia A. Darrah, Chetan Seshadri	2021	16
12	Immune correlates of tuberculosis disease and risk translate across species Science Translational Medicine ·Mushtaq Ahmed, Shyamala Thirunavukkarasu, Bruce A. Rosa, Kimberly A. Thomas, Shibali Das, Javier Rangel‐Moreno, Lan Lu, Smriti Mehra, Stanley Kimbung Mbandi, Larissa B. Thackray, Michael Diamond, Kenneth M. Murphy, Terry K. Means, John Martin, Deepak Kaushal, Thomas J. Scriba, Makedonka Mitreva, Shabaana A. Khader	2020	45
13	Analyzing the Mycobacterium tuberculosis immune response by T-cell receptor clustering with GLIPH2 and genome-wide antigen screening Nature Biotechnology ·Huang Huang, Chunlin Wang, Florian Rubelt, Thomas J. Scriba, Mark M. Davis	2020	242
14	Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study PLoS Medicine ·Adam Penn‐Nicholson, Thomas Hraha, Ethan Thompson, David Sterling, Stanley Kimbung Mbandi, Kirsten Wall, Michelle Fisher, Sara Suliman, Steven G. Smith, Willem A. Hanekom, Nebojša Janjić, Mark Hatherill, Stefan H. E. Kaufmann, Jayne S. Sutherland, Gerhard Walzl, Mary Ann De Groote, Urs A. Ochsner, Daniel E. Zak, Thomas J. Scriba, (unknown)	2019	68
15	MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by Mycobacteria The Journal of Immunology ·Sara Suliman, Melissa Murphy, Munyaradzi Musvosvi, Anele Gela, Erin W. Meermeier, Hennie Geldenhuys, Christiaan Hopley, Asma Toefy, Nicole Bilek, Ashley Veldsman, Willem A. Hanekom, John L. Johnson, W. Henry Boom, Gerlinde Obermoser, Huang Huang, Mark Hatherill, David Lewinsohn, Elisa Nemes, Thomas J. Scriba	2019	47
16	Performance of host blood transcriptomic signatures for diagnosing and predicting progression to tuberculosis disease in HIV-negative adults and adolescents: a systematic review protocol BMJ Open ·Humphrey Mulenga, Erick Wekesa Bunyasi, Stanley Kimbung Mbandi, Simon C. Mendelsohn, Benjamin M. Kagina, Adam Penn‐Nicholson, Thomas J. Scriba, Mark Hatherill	2019	5
17	Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial American Journal of Respiratory and Critical Care Medicine ·Sara Suliman, Angelique Kany Kany Luabeya, Hennie Geldenhuys, Michèle Tameris, Søren T. Hoff, Zhongkai Shi, Dereck Tait, Ingrid Kromann, Morten Rühwald, Kathryn Rutkowski, Barbara Shepherd, David A. Hokey, Ann M. Ginsberg, Willem A. Hanekom, Peter Andersen, Thomas J. Scriba, Mark Hatherill	2018	76
18	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention Tuberculosis ·Andrew Fioré-Gartland, Lindsay N. Carpp, Kogieleum Naidoo, Ethan Thompson, Daniel E. Zak, Steve Self, Gavin Churchyard, Gerhard Walzl, Adam Penn‐Nicholson, Thomas J. Scriba, Mark Hatherill	2017	19
19	Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin (BCG) for Infants of HIV Infected Mothers: A Phase 2 Randomized Controlled Trial. Clinical Infectious Diseases ·Elisa Nemes, A C Hesseling, Michèle Tameris, Katya Mauff, Katrina Downing, Humphrey Mulenga, P. Rose, Marieke van der Zalm, Sharon Mbaba, Davis AS, Willem A. Hanekom, Gerhard Walzl, Thomas J. Scriba, Helen McShane, Mark Hatherill	2017	1
20	Prevalence of latent TB infection and TB disease among adolescents in high TB burden countries in Africa: a systematic review protocol BMJ Open ·Erick Wekesa Bunyasi, Bey‐Marrié Schmidt, Leila Abdullahi, Humphrey Mulenga, Michèle Tameris, Angelique Kany Kany Luabeya, Justin Shenje, Thomas J. Scriba, Hennie Geldenhuys, Robin Wood, Mark Hatherill	2017	3

About Thomas J. Scriba

Thomas J. Scriba is a scholar working on Infectious Diseases, Immunology, Virology, Epidemiology and Surgery, having authored 206 papers that have together received 9.2k indexed citations. Recurring topics across this work include Tuberculosis Research and Epidemiology (130 papers), Mycobacterium research and diagnosis (58 papers), Immunodeficiency and Autoimmune Disorders (53 papers), Immune responses and vaccinations (39 papers), Immune Cell Function and Interaction (38 papers), T-cell and B-cell Immunology (30 papers), vaccines and immunoinformatics approaches (24 papers) and Diagnosis and treatment of tuberculosis (21 papers). The work is most often cited by research in Infectious Diseases (5.6k citations), Immunology (5.2k citations), Virology (520 citations), Epidemiology (3.5k citations) and Molecular Biology (1.9k citations). Thomas J. Scriba has collaborated with scholars based in South Africa, United States and United Kingdom. Frequent co-authors include Willem A. Hanekom, Mark Hatherill, Gregory Hussey, Hassan Mahomed, Gerhard Walzl, Michèle Tameris, Helen McShane, Mark M. Davis, Huang Huang and Sebastian Gelderbloem. Their work appears in journals such as Frontiers in Immunology, The Journal of Immunology, PLoS ONE, American Journal of Respiratory and Critical Care Medicine and Vaccine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact